Marc E Hoffman, DO - Everett & Hurite Ophthalmic

Dr. Omar Abbasi is a specialist in the medical and surgical treatment of glaucoma and is a practicing eye doctor at Everett & Hurite Ophthalmic Association. A Michigan native, he graduated with honors from the University of Michigan and received his medical degree from the University of Michigan Medical School.Dr. Abbasi completed his ophthalmology residency at the Kresge Eye Institute in Detroit, Michigan, where he was elected as chief resident his final year. He then trained under renowned glaucoma specialist Dr. Michael Kass at the Washington University Eye Center in Saint Louis, Missouri, where he completed a fellowship in glaucoma and anterior segment surgery.Dr. Abbasi has extensive experience with glaucoma lasers including both argon and selective laser trabeculoplasty (ALT and SLT), and endocyclophotocoagulation (ECP). He performs trabeculectomies, as well as the placement of ExPRESS mini-shunts and glaucoma drainage implants.Dr. Abbasi also is available for general eye care and consultation. He sees patients at his Pittsburgh, Greensburg, Monroeville, McMurray, Rostraver and Wheeling locations.

Dr. Kondapalli is a specialist in the medical treatment of retinal diseases with additional training in treatment of ocular tumors and cancers. He has been practicing at Everett & Hurite Ophthalmic Association in over 5 different offices in PA and WV. A Cleveland, Ohio native, he graduated from The Ohio State University and received his medical degree from The Ohio State University College of Medicine. Having an interest in ophthalmology at a young age, Dr. Kondapalli has presented at national and international meetings since 2006.Dr. Kondapalli completed his ophthalmology residency at Loyola University Medical Center in Chicago, Illinois. He then returned to Ohio to complete a fellowship in medical retina and ocular oncology in through The Havener Eye Institute at The Ohio State University Wexford Medical Center. He has extensive experience in treatment of macular degeneration, retinal vein occlusions, and diabetic retinopathy. He was actively involved in clinical trials and is up to date on the most current treatment modalities.